What's happening with the Little Green Pharma (ASX:LGP) share price today?

The medicinal cannabis producer has failed to fly today after posting its latest quarterly results.

| More on:
A white cannabis leaf set against a green background with a graph going up, indicating a rising share price for ASX cannabis shares

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Little Green Pharma Ltd (ASX: LGP) share price has edged lower today after the company released its quarterly results.

Little Green shares finished yesterday's close at 84 cents, before dropping to an intraday low of 80 cents after the market open. Currently, the Little Green Pharma share price is trading flat at 81 cents.

Here we cover the moving parts in Little Green Pharma's results in finer detail.

Quick recap on Little Green Pharma

Little Green Pharma is a medicinal cannabis pure-play that cultivates and produces products for the medicinal cannabis industry.

It also has a hand in research and development (R&D) plus the manufacturing and distribution of these products in the Australian market.

The company's operations are vertically integrated, meaning it has full control over its entire supply chain for efficiency purposes.

Little Green Pharma has a market capitalisation of $188 million at the time of writing.

Little Green's quarterly results

The company recognised revenue of $600,000 this quarter, with cash receipts totalling $1.82 million, up 20% from the previous quarter.

The discrepancy between revenue and cash receipts boils down to "a change in wholesaling agreements" that the company realised this quarter.

In a nutshell, Little Green had to revise its agreements with all Australian distribution partners after the Therapeutic Goods Association (TGA) updated its clarifications "regarding wholesaling rules for unregistered medicines".

The change enforces the company to recognise revenue only when its product is sold to the pharmacy, instead of when it is sold to the wholesaler.

Consequently, the company recognised a significant down-step in revenue from the previous quarter, when it recorded revenue of $2.3 million.

Little Green anticipates revenue trends to normalise by the next quarter and estimates revenue of $3 million for Q1 FY22.

Additional takeouts

In other recent updates, Little Green last week completed the acquisition of a medicinal cannabis facility in Denmark for $10.9 million.

As a result, it recorded increased production and staff costs "associated with the Denmark facility".

Little Green labelled the facility as "one of the largest production assets in Europe". In addition to improving efficiency, it produced more than 20 tonnes of biomass annually, including over 12 tonnes of "dried cannabis flower".

Offsetting these expenditures, the company completed a capital raise of $26 million "net of costs", with "strong support from institutional and sophisticated investors".

Moreover, Little Green realised a "record growth in underlying patient demand", adding a 37% increase to new patients and 25% increase in dispensed products.

This brings the total of new patients and products dispensed to 3,300 and 11,200 respectively.

Little Green Pharma share price snapshot

The Little Green Pharma share price has posted a year to date return of 43%, extending the previous 12 month's return of 122%.

These returns have outpaced the S&P/ASX 200 Index (ASX: XJO)'s return of ~23% over the past year.

Additionally, Little Green finished the quarter with $40 million in cash on its balance sheet.

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Burgundy Diamond Mines, Clarity Pharmaceuticals, EML, and Zip are sinking today

These ASX shares are ending the week in the red. But why?

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

a young boy dressed up in a business suit and tie has a cute grin and holds two fingers up.
Opinions

2 of my top ASX 200 shares to consider buying before April

I would happily exchange dollars for these two shares right now.

Read more »

Father in the ocean with his daughters, symbolising passive income.
Dividend Investing

I'd spend $8k on these ASX 200 shares today to target a $6,102 annual passive income

I believe these ASX 200 shares will continue rewarding passive income investors for years to come.

Read more »

Three businesspeople leap high with the CBD in the background.
Share Market News

Boom! ASX 200 blasts to new record highs

ASX 200 investors just sent the benchmark index into uncharted territory.

Read more »